News

MedPage Today1h
First Oral Therapy for Rare Adrenal Gland Tumors Gets Green Light From FDA
The action establishes belzutifan as the only approved oral therapy for PPGL. The approval stipulates use in adults and children 12 years or older with locally advanced, unresectable, or metastatic ...
Medscape1d
FDA Okays Belzutifan for Pheochromocytoma or Paraganglioma
The US Food and Drug Administration (FDA) has approved belzutifan (Welireg, Merck) for adult and pediatric patients aged 12 ...
Healthline1d
FDA Accepts Novo Nordisk’s Application for Oral Wegovy: 5 Things to Know
Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...
US FDA approves AbbVie's drug for a type of lung cancer
The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received ...
Everyday Health2d
Zepbound Beats Wegovy for Weight Loss in First Head-to-Head Trial
In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.
Targeted Oncology2d
FDA Approves Belzutifan in Advanced Pheochromocytoma and Paraganglioma
The FDA approved belzutifan as the first oral therapy for advanced or metastatic pheochromocytoma and paraganglioma in ...